<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137835">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01849081</url>
  </required_header>
  <id_info>
    <org_study_id>2013P000688</org_study_id>
    <nct_id>NCT01849081</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver</brief_title>
  <official_title>Evaluating the Efficacy of CPAP Therapy for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are doing this research study to evaluate whether continuous positive airway pressure
      (CPAP), a treatment for sleep apnea, will also help treat fatty liver disease. Sleep apnea
      is a disease where a person has interruptions in their breathing while they are sleep. This
      can lead to low oxygen levels in the blood. CPAP is a mask that delivers oxygen at high
      pressure to the lungs to prevent a decrease in blood oxygen levels. CPAP is a known
      treatment for sleep apnea.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Steatosis by MRS</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects will undergo baseline and 12 week magnetic resonance spectroscopy to assess the impact of CPAP or diet on fatty liver.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm with receive treatment with CPAP for fatty liver disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the lifestyle arm will undergo 12 weeks of dietary counseling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.</description>
    <arm_group_label>CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>LIfestyle</intervention_name>
    <description>Subjects will undergo 12 weeks of dietary counseling.</description>
    <arm_group_label>Lifestyle Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years of age or older with a previous liver biopsy showing NASH and at
             least grade 2 steatosis

          -  Obstructive sleep apnea diagnosed by sleep study.

        Exclusion Criteria:

          -  Other  causes of chronic liver disease

          -  cirrhosis

          -  less than 33% steatosis identified on magnetic resonance spectroscopy (MRS)

          -  Alcohol use &gt;2 units per day for women or &gt;3 units per day for men

          -  Intolerance to or refusal of CPAP therapy

          -  overnight desaturation (more than 10% of the sleep time with oxygen desaturation
             below 85%)

          -  underlying sever sleepiness (Epworth scale more than 15)

          -  uncontrolled hypertension

          -  Severe heart failure (ejection fracture less than 30%)

          -  cardiac arrhythmias (atrial fibrillation or history of ventricular tachycardia)

          -  those who are commercial drivers
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen E Corey, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen E Corey, MD</last_name>
      <phone>617-724-1685</phone>
      <email>kcorey@partners.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen E Corey, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 7, 2013</lastchanged_date>
  <firstreceived_date>May 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Kathleen E Corey</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <keyword>Non-alcoholic fatty liver disease</keyword>
  <keyword>Obstructive sleep apnea</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
